Dapagliflozin for kidney AL amyloidosis
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in Michigan.
- You have been diagnosed with kidney AL amyloidosis (confirmed by biopsy) with at least 1 gram of protein in your urine daily.
- Your kidney function is stable or improving (plateau) for at least 3 months before joining.
- You are not on diabetes treatment (type 1 or 2).
- You have not taken dapagliflozin or similar drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This trial tests if dapagliflozin, a medication that lowers blood sugar and protects the kidneys, can reduce protein in the urine of children with inherited kidney disease. It may help preserve kidney function when added to standard blood pressure medication.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
Hear when a new Renal AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.